Skip to content
lifestyle.smarttalksuccess.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
IGC Pharma, Inc.
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
May 4, 2026
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
May 3, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease
April 7, 2026
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
March 31, 2026
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
February 17, 2026
IGC Pharma Announces Equity Research Update by Alliance Global Partners
February 16, 2026
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation
February 10, 2026
←
Previous Page
1
2